FDA has approved Evkeeza injection to Regeneron as an add-on treatment for patients 12 years and older with genetic condition that causes severely high cholesterol.
- Effectiveness and safety of Evkeeza were evaluated in a double-blind, randomized, placebo-controlled, 24-week trial enrolling 65 patients with homozygous familial hypercholesterolemia (HoFH)
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.